Immunotherapy for Allergic Rhinitis



Specific allergen immunotherapy (SIT) is demonstrated to decrease symptoms of allergic rhinitis (AR), allergic asthma, conjunctivitis, and allergy for stinging insects in long term. It reduces allergen sensitivity, and usually alleviates allergic symptoms even after the end of the treatment. Therefore, it is an effective and profitable management for many of allergic individuals. SIT includes repetitive administration of allergen extracts for decreasing the symptoms upon subsequent allergen exposures. It improves quality of life (QoL), and produces long-term allergen tolerance. Careful patient selection is important for a successful outcome. SIT is a safe treatment option if sufficient precautions are taken. SIT is recommended in individuals with measurable specific IgE antibodies against allergens that are clinically relevant. Employment of SIT depends on several patient-related variables, including, but not limited to, preference/acceptability, compliance to treatment, need for medications, improvement with allergen protective actions, and side effects of medicines. Effectiveness of SIT in AR has been proven in prospective, randomized, placebo-controlled, single- or double-blind, studies. Randomized, double-blind, placebo-controlled prospective trials have demonstrated beneficial effects of SIT in treatment of allergic asthma. It is effective in most allergic patients if suitable allergy workup has been performed. The main SIT types are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).


Specific allergen immunotherapy (SIT) Allergen Specific IgE antibodies Subcutaneous immunotherapy (SCIT) Sublingual immunotherapy (SLIT) 


  1. 1.
    Allergy Shots (Immunotherapy). American Academy of Allergy, Asthma & Immunology. (Received online at 21, Nov, 2014).
  2. 2.
    Cingi C, Muluk NB, Hanci D, Ulusoy S, Sahin F. Updating the role played by immunotherapy for allergic rhinitis: meta-analysis. Int Forum Allergy Rhinol. 2015;5(2):132–42. Epub 2014 Nov 25.CrossRefPubMedGoogle Scholar
  3. 3.
    Walker SM, Durham SR, Till SJ, British Society for Allergy and Clinical Immunology, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011;41(9):1177–200.PubMedCrossRefGoogle Scholar
  4. 4.
    Cox L, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol. 2011:S1–S55.Google Scholar
  5. 5.
    Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Ther. 2000;22:342–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936.I.Google Scholar
  7. 7.
    Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186.Google Scholar
  8. 8.
    Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther. 2000;22:329–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;4:CD001186.Google Scholar
  10. 10.
    Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969–74.PubMedGoogle Scholar
  11. 11.
    Hanci D, Şahin E, Muluk NB, Cingi C. Immunotherapy in all aspects. Eur Arch Otorhinolaryngol. 2016;273(6):1347–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010;104:79–85.PubMedCrossRefGoogle Scholar
  13. 13.
    Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol. 2008;121:227–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Ariano R, Berto P, Tracci D, Incorvaia C, Frati F. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc. 2006;27:159–63.PubMedGoogle Scholar
  15. 15.
    van de Veen W, Akdis M. Mechanisms of immune regulation in allergy. In: Akdis CA, Agache I, editors. Global Atlas of Allergy, Part 23, Published by the European Academy of Allergy and Clinical Immunology; 2014. p. 90–1.; Accessed 2 Jul 2015.
  16. 16.
    Kuna P, Alam R, Kuzminska B, Rozniecki J. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: Results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol. 1989;83:816–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Greenberger PA. Use of immunotherapy for allergic disorders. Immunol Allergy Clin N Am. 1992;12:1–12.Google Scholar
  18. 18.
    Creticos PS. Immunologic changes associated with immunotherapy. Immuno. Allergy Clin North Am. 1992;12:13–37.Google Scholar
  19. 19.
    Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993;92:644–51.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol. 1997;27:1131–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Blaser K, Akdis CA. Interleukin-10, T regulatory cells and specific allergy treatment. Clin Exp Allergy. 2004;34:328–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Francis JN, Till SJ, Durham SR. Induction of IL-101CD41CD251 T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111:1255–61.PubMedCrossRefGoogle Scholar
  23. 23.
    Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Savolainen J, Laaksonen K, Rantio-Lehtimaki A, Terho EO. Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy. 2004;34:413–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Francis J, James L, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008;121:1120–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hay fever. J Clin Invest. 1976;57:1378–85.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Till SJ, Durham SR. Immunological responses to allergen immunotherapy. Clin Allergy Immunol. 2004;18:85–104.PubMedGoogle Scholar
  28. 28.
    Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025–35.PubMedCrossRefGoogle Scholar
  29. 29.
    Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD41 T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 1996;97:1356–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA1 cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol. 1997;99:254–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Saito H.Innate Lymphoid cells. In: Akdis CA, Agache I, editors. Global Atlas of Allergy. Part 8, Published by the European Academy of Allergy and Clinical Immunology; 2014. p. 50–2.; Accessed 2 July 2015.
  32. 32.
    Wilson DR, Irani AM, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy. 2001;31:1705–13.PubMedCrossRefGoogle Scholar
  33. 33.
    Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest. 1973;52:472–82.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172:3252–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 response associated with mucosal TGF-expression. J Immunol. 2007;178:4658–66.PubMedCrossRefGoogle Scholar
  36. 36.
    Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods. 2006;317:71–9.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Wilson DR, Irani AM, Walker SM, Jacobson MR, Mackay IS, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy. 2001;31:1705–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol. 1991;88:27–32.PubMedCrossRefGoogle Scholar
  39. 39.
    Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003;33:1198–208.PubMedCrossRefGoogle Scholar
  40. 40.
    Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, et al. Relation of CD4_CD25_ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet. 2004;363:608–15.PubMedCrossRefGoogle Scholar
  41. 41.
    Robinson DS, Larche´ M, Durham SR. Tregs and allergic disease. J Clin Invest. 2004;114:1389–97.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936.Google Scholar
  43. 43.
    Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. J Allergy Clin Immunol. 1990;86:292–305.PubMedCrossRefGoogle Scholar
  44. 44.
    Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol. 1997;7:90–7.PubMedGoogle Scholar
  45. 45.
    Peroni DG, Piacentini GL, Martinati LC, Warner JO, Boner AL. Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy. 1995;50:925–30.PubMedCrossRefGoogle Scholar
  46. 46.
    Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15:9–16.PubMedGoogle Scholar
  47. 47.
    Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006;61:1162–72.PubMedCrossRefGoogle Scholar
  48. 48.
    Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy. 1999;54:1022–41.PubMedCrossRefGoogle Scholar
  49. 49.
    Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol. 2004;113:643–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003;2:CD002893.Google Scholar
  51. 51.
    Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001;87:47–55, IIIPubMedCrossRefGoogle Scholar
  52. 52.
    Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy. 2007;62(8):958–61.PubMedCrossRefGoogle Scholar
  53. 53.
    Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Scadding GW, Caldaron MA, Shamji MH, et al. Effect of two years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at three years among patients with moderate to severe seasonal allergic rhinitis: The GRASS randomizes clinical trial. JAMA. 2017;317(6):615–25.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T. Sub-Lingual Immunotherapy, World Allergy Organization Position Paper 2009. WAO J. 2009:233–81.Google Scholar
  56. 56.
    Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med. 1999;341:468–75.PubMedCrossRefGoogle Scholar
  57. 57.
    Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy. 1996;51:430–3.PubMedGoogle Scholar
  58. 58.
    Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Bufe A, Eberle P, Franke-Beckmann E, et al. Phase III trial with grass allergen tablet for sublingual immunotherapy in children. J Allergy Clin Immunol. 2008;121:S127.CrossRefGoogle Scholar
  60. 60.
    Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008;63:5–34.PubMedCrossRefGoogle Scholar
  61. 61.
    Bahceciler NN, Cobanoglu N. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma. Immunotherapy. 2011;3(6):747–56. Scholar
  62. 62.
    Aberer W, Hawranek T, Reider N, Schuster C, Sturm G, Kranke B, Immunoglobulin E. G antibody profile to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol. 2007;17(3):131–6.PubMedGoogle Scholar
  63. 63.
    Laffer S, Spitzauer S, Susani M, Pairleitner H, Schweiger C, Gronlund H, Menz G, Pauli G, Ishii T, Nolte H, Ebner C, Sehon AH, Kraft D, Eichler HG, Valenta R. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J Allergy Clin Immunol. 1996;98(3):652–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Emminger W, Hernández MD, Cardona V, Smeenk F, Fogh BS, Calderon MA, de Blay F, Backer V. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease. Int Arch Allergy Immunol. 2017;174(1):35–44.Google Scholar
  65. 65.
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558–62.PubMedCrossRefGoogle Scholar
  66. 66.
    Malling H, Immunotherapy WB. Position paper of the European academy of allergy and clinical immunology. Allergy. 1993;48(Suppl 14):9–35.CrossRefGoogle Scholar
  67. 67.
    Global strategy for asthma management and prevention. GINA. Update from NHLBI/WHO Workshop Report 1995, Revised 2006. 2006.
  68. 68.
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl):S147–334.PubMedCrossRefGoogle Scholar
  69. 69.
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and Aller-Gen). Allergy. 2008;63(Suppl 86):8–160.PubMedCrossRefGoogle Scholar
  70. 70.
    Desensitising vaccines: an allergist’s view. Br Med J (Clin Res Ed). 1986;293:1169–70.Google Scholar
  71. 71.
    British Thoracic Society (BTS). Guideline on the management of asthma. Thorax. 2008;63(Suppl. 4):iv1–121.Google Scholar
  72. 72.
    Blaiss MS. Management of rhinitis and asthma in pregnancy. Ann Allergy Asthma Immunol. 2003;90:16–22.PubMedCrossRefGoogle Scholar
  73. 73.
    Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the world allergy organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125:569–74.PubMedCrossRefGoogle Scholar
  74. 74.
    Malling HJ, Weeke B. Immunotherapy (Position Paper). Allergy. 1993;48:9–35.CrossRefGoogle Scholar
  75. 75.
    Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004;113:1129–36.PubMedCrossRefGoogle Scholar
  76. 76.
    Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy. 2001;56(10):989–92.PubMedCrossRefGoogle Scholar
  77. 77.
    Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005;35(5):560–4.PubMedCrossRefGoogle Scholar
  78. 78.
    Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol. 2007;119(4):881–91.PubMedCrossRefGoogle Scholar
  79. 79.
    Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35:565–71.PubMedCrossRefGoogle Scholar
  80. 80.
    Cox LS, Larenas LD, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021–35.PubMedCrossRefGoogle Scholar
  81. 81.
    Lombardi C, Gargioni S, Cottini M, Canonica GW, Passalacqua G. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy. 2008;63:375–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Ibanez MD, Kaiser F, Knecht R, et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol. 2007;18:516–22.PubMedCrossRefGoogle Scholar
  83. 83.
    Finegold I. Immunotherapy: when to initiate treatment in children. Allergy Asthma Proc. 2007;28:698–705.PubMedCrossRefGoogle Scholar
  84. 84.
    Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61:855–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:274–80.PubMedCrossRefGoogle Scholar
  87. 87.
    Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64:1394–401.PubMedCrossRefGoogle Scholar
  88. 88.
    Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy. 1986;41:271–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Valovirta E, Berstad AKH, de Blic J, Bufe A, Eng P, Halken S, Ojeda P, Roberts G, Tommerup L, Varga E-M, Winnergard I. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardised grass allergy immunotherapy tablet in children with grass pollen induced allergic rhino-conjunctivitis. Clin Ther. 2011;33:1537–46.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of OtorhinolaryngologyÇiğli Regional Education HospitalİzmirTurkey
  2. 2.Eskişehir Osmangazi University, Medical FacultyDepartment of OtorhinolaryngologyEskisehirTurkey
  3. 3.RNTNE Hospital, University College Hospitals LondonLondonUK

Personalised recommendations